Amgen submits Otezla supplementary new drug application, indications extended to mild to moderate psoriasis
Time of Update: 2021-03-24
The results of the test showed that compared with placebo, at week 16, the sPGA skin score of patients who applied 30 mg of Otezla twice a day achieved a statistically significant improvement, and the test reached the primary endpoint.
An imported anti-inflammatory drug Otezla submits an application in the United States for the treatment of mild to moderate plaque psoriasis
Time of Update: 2021-03-22
ADVANCE (PSOR-022) is a multicenter, randomized, placebo-controlled, double-blind phase 3 study that evaluates the efficacy and safety of Otezla in the treatment of mild to moderate plaque psoriasis.
New target IL-36R, a new drug for psoriasis, a phase II study failed
Time of Update: 2021-03-22
On March 8, AnaptysBio announced that the top-line data of the phase II clinical study (POPLAR) of the anti-IL-36R monoclonal antibody imsidolimab for the treatment of moderate to severe palmoplantar pustulosis (PPP) did not meet the primary endpoint.
The long-term effect of "first-in-class" psoriasis external therapy is obvious...
Time of Update: 2021-03-07
Today, Dermavant Sciences announced that the company's tapinarof emulsion (1%) has obtained positive results in an interim analysis of long-term open labeling studies for adult patients with plaque-like psoriasis.
The phase III drug study of Psoriasis in BMS met the standard
Time of Update: 2021-03-06
POETYK PSO-1 is the first of two global III studies to assess the safety and effectiveness of deucravacitinib in patients with moderate to severe plaque-like psoriasis compared to placebo and Otezla .
The long-term effect of "first-in-class" psoriasis external therapy is significant
Time of Update: 2021-02-23
of only 254 Da, with good skin permeability. aromatic hydrocarbons have an important role to play in regulating autoimmune response. Tapinarof inhibits the inflammatory response mediated by IL-17 by regulating the function of aromatic receptors
GSK sells psoriasis/dermatitis therapy to Dermavant
Time of Update: 2021-02-22
Said: "Tapinarof has the potential to be a first-class treatment and a daily topical drug that can delay or even eliminate systemic treatments for psoriasis and endexual dermatitis.
The new anti-inflammatory drug TYK2 inhibitor BMS-986165 treats moderate to severe plaque psoriasis Phase II clinical:
Time of Update: 2021-02-15
The study was conducted in a multi-center, randomized, double-blind, placebo-controlled, parallel group study in adult patients with moderate to severe plaque-type psoriasis to assess the clinical efficacy and safety of BMS-986165.
New drug for psoriasis! Bryhali (halophetamine, 0.01% emulsion) is available in the United States
Time of Update: 2021-02-14
The safety of Bryhali lotions has been confirmed in clinical studies, patients with a daily local medication for 8 weeks of continuous treatment, showing good tolerance, and no increase in skin atrophy.
New drug for psoriasis! The Lancet back-to-back IL-17A/F inhibitor bimekizumab study: Better than Stelara!
Time of Update: 2021-02-13
February 06, 2021 // -- UCB recently announced that the results of two Phase 3 studies (BE VIVID, BE READY) evaluating the treatment of adult patients with moderate to severe plaque psoriasis with the new anti-inflammatory drug bimekizumab have been
New anti-inflammatory drugs! Baishi Meishi Guibao oral TYK2 inhibitor deucravacitinib treatment plaque psoriasis 2 phase 3 clinical success!
Time of Update: 2021-02-13
study evaluated the efficacy and safety of deucravacitinib (6 mg once daily) in treating patients with moderate to severe plaque-type psoriasis patients and compared it with placebo and Otezla (apremilast, 30 mg, 2 times a day). results showed
Molecular findings show the prospect of psoriasis gene therapy
Time of Update: 2021-02-12
This of psoriasis, which is caused by the overbreeding of skin cells.
Better than the common oral therapy TYK2 structure inhibitors to treat psoriasis reached the clinical end of phase 3
Time of Update: 2021-02-11
1020 patients in a randomized double-blind trial called POETYK PSO-2 assessed the efficacy and safety of deucravacitinib compared to placebos and common PDE4 inhibitors.
UCB published the latest data in Lancet on the treatment of plaque-like psoriasis
Time of Update: 2021-02-10
FDA and EMA accepted the company's Application for Biological Agent Licensing (BLA) and Market Licensing (MAA) for bimekizumab, a moderate to severe plaque-like psoriasis, respectively, in September 2020.
Shenzhen Longgang uses fluorosilicon anti-paste coating to cure "psoriasis"
Time of Update: 2021-02-05
China Paint Network News: Recently, Longcheng Street City Construction Office using the third generation of new materials "fluorosilicon" anti-paste coating , is expected to cure "psoriasis." The paint will be used in the next step
Shenzhen Longgang fluorosilicon anti-paste coating root cure "psoriasis"
Time of Update: 2021-02-04
China Coatings Network News: Recently, Longcheng Street City Construction Office used the third generation of new materials "fluorosilicon" anti-paste paint , is expected to cure "psoriasis." The paint will be used in the next
Johnson and Johnson 2020 results: Stelara psoriasis adaptation revenue accelerates decline...
Time of Update: 2021-02-01
Topag continued to lead the rise; central nervous system, steady, 3.5%. based on Johnson and Johnson's 2020 financial results, this paper provides a brief review of the two most important disease areas in Johnson and Johnson's current
AbbVie JAK inhibitors have been approved to treat psoriasis arthritis and severe spina blinitis
Time of Update: 2021-01-30
in two Phase 3 clinical trials, SELECT-PsA1 and SELECT-PsA2, Rinvoq reached the primary endpoint in adult patients with active psoriasis arthritis with poor DMARD efficacy.
Science Paper Interpretation! Reveals the developmental origins of eczema and psoriasis
Time of Update: 2021-01-29
to understand how the skin is formed and how it is associated with adult health and disease, the researchers studied cells from developing skin that were compared to biopsy samples from healthy adults and patients with eczema and psoriasis.
New anti-inflammatory drugs! AbbVie IL-23 inhibitor Skyrizi treats psoriasis arthritis 2 Phase III studies have been successful!
Time of Update: 2021-01-18
January 07, 2021 // -- AbbVie recently announced positive topline results for two Phase 3 studies (KEEPsAKE-1 and KEEPsAKE-2) evaluating the treatment of active psoriasis arthritis (PsA) adult patients with the new anti-inflammatory drug IL-23 inhibitor Skyrizi (risankizumab).